Low Cost Synthesis of Lomustine Under Continuous Flow Conditions

Back to all technologies
Download as PDF
2019-THOM-68395
Lomustine is a commercially available drug used to treat Hodgkin's lymphoma and brain tumors. According to Wall Street Journal, the price has increased over 1400 percent over the past 5 years which has made it unaffordable to many patients. The company currently selling Lomustine stated that one reason for the price hike is growing operational costs associated with the drug. Since lomustine has no generic competitors, there is a need for lower production cost of lomustine to make this treatment economical for patients.

Researchers at Purdue University have developed a continuous manufacturing process for lomustine that has a short residence time and 63 percent yield. Major advantages of this process are that the total production cost for lomustine is lower, the product is higher quality, and the manufacturing operation is safer for production personnel.

Advantages:
- Control of purity
- Continuous manufacturing

Potential Applications:
- Pharmaceutical manufacturing
Oct 16, 2018
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org